Cytiva and Fida Biosystems Partner to Accelerate Drug Discovery Through Combined Analytical Platform
Key Insights
Cytiva (search) and Danish company Fida Biosystems (search) have formed a collaboration to combine Biacore (search) surface plasmon resonance systems with Flow-Induced Dispersion Analysis technology for enhanced protein research capabilities.
The partnership provides researchers with both complementary and orthogonal analytical approaches, linking structural details like protein size and stability with precise binding and interaction data.
Fida Biosystems (search) has demonstrated strong commercial momentum with over 100 instruments sold, revenues doubling in the past year, and recently secured a €5 million Series A extension led by Swedish FSG fund.
Cytiva (search), a Danaher (search) company and leader in the life sciences industry, has announced a strategic collaboration with Danish molecular analysis specialist Fida Biosystems (search) to expand analytical capabilities for protein research. The partnership combines Cytiva's established Biacore (search) surface plasmon resonance (SPR) systems with Fida Biosystems' innovative Flow-Induced Dispersion Analysis (FIDA (search)) technology, creating a comprehensive analytical platform designed to accelerate drug discovery timelines.
Enhanced Molecular Characterization Platform
The collaboration provides researchers with both complementary and orthogonal analytical approaches that deliver a more complete picture of molecular interactions. By linking structural details such as protein size and stability with precise binding and interaction data, scientists can make faster, more confident decisions earlier in the development process.
"Combining technologies with Cytiva (search) fosters deeper insight, giving researchers greater confidence in their results," said Brian Sørensen, CEO of Fida Biosystems (search). "This collaboration supports our mission to advance biophysical analysis and empower scientists with faster, more informative data for complex molecular research."
Tim Bervoets, President of Discovery & Medical at Cytiva (search), emphasized the practical benefits of the partnership: "Researchers need to understand how their molecules behave, and they need that insight quickly. Pairing Biacore (search) SPR with FIDA (search) measurements gives them a more complete picture, without adding complexity. It's a practical step forward that supports confident decisions and keeps workflows moving. In essence, it helps accelerate the researcher's time to insight."
FIDA Technology Advantages
At the core of Fida Biosystems (search)' offering is Flow-Induced Dispersion Analysis, a first-principles, in-solution method for characterizing biomolecules and nanoparticles. Unlike traditional techniques, FIDA (search) requires no surface immobilization or pre-defined models. The technology uses laminar flow and Taylor dispersion in a microcapillary to deliver precise, quantitative insights into molecular behavior in complex matrices such as plasma, serum, or cell lysates.
The immobilization-free, in-solution approach allows measurement of binding affinity, complex formation, aggregation, and sample integrity without surface artifacts. The platform performs reliably in challenging or viscous samples while consuming minimal material. The latest Fida (search) Neo instrument adds in-solution kinetic measurements, enabling determination of association (k-on) and dissociation (k-off) rates, providing deeper insight into drug-target interactions for early candidate selection and optimization.
Strong Commercial Momentum
Fida Biosystems (search) has demonstrated significant market traction with rapid adoption across pharmaceutical, biotechnology, and academic laboratories. The company has sold over 100 instruments and achieved doubled revenues in the past year. This commercial success has attracted substantial investor interest, with the company recently securing a €5 million extension to its Series A funding round.
Swedish Fåhraeus Startup and Growth Fund (search) (FSG) joined as the new lead investor in the Series A extension, alongside existing backer EIFO (search). The funding will accelerate adoption of Fida (search)'s platform and prepare the company for a future Series B round amid strong revenue and instrument sales growth.
Applications in Complex Molecule Research
The combined platform is particularly valuable for research on complex molecules, including bispecific antibodies (search) and degraders (search). Fidabio's technology provides critical information on sample quality that complements Biacore (search) SPR system data. This integrated approach helps researchers understand both the structural characteristics and binding properties of their molecules, improving confidence in experimental results while accelerating research timelines.
The collaboration represents a strategic alignment between two companies focused on advancing analytical capabilities in drug discovery, with Cytiva (search)'s established market presence in SPR technology complementing Fida Biosystems (search)' innovative in-solution analysis platform.